Stockreport

Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update

Opus Genetics, Inc.  (IRD) 
PDF In October, Ocuphire Pharma acquired Opus Genetics, creating a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited r [Read more]